Paxman’s recent public offer to acquire its competitor Dignitana has been accepted, signifying a historical milestone for the two companies and heralding the start of a brand-new chapter of working together to advance side effect management for cancer patients around the world.
Paxman and Dignitana will now combine, creating a stronger, unified company – Paxman AB This exciting merger will bring improved collaborations and connections, sharing new perspectives and strengths, working together as one team to improve patient outcomes.
For many years, Paxman and Dignitana have been active in the field of side effect management, specifically scalp cooling, as clear leaders in the market, sharing similar patient-centric goals and visions.
The unified company is committed to providing consistent service levels with greater resource and enhanced R&D capacity through greater investment.
Currently, Paxman and Dignitana’s scalp cooling devices treat only 1% of applicable patients, signifying a huge opportunity for growth, with clear synergies enabling further investment in market expansion and research and development.
Combining the best parts of each of the companies brings not only commercial and geographical benefits but also customer and patient benefits.
Richard Paxman OBE, CEO of Paxman, said: “This merger marks a pivotal point in the history of our two companies and the beginning of a brand-new chapter as we unite to form one stronger, unified team. I am truly looking forward to collaborating, connecting, and combining the best of our two organisations, with new perspectives and shared strengths as we move forward.”
The aligned vision of these two scalp cooling industry leaders will combine the unique strengths of both companies, positioned to accelerate these shared goals, whilst creating deeper, more meaningful impact.
